Navigation Links
Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
Date:8/29/2008

CRANBURY, N.J., Aug. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced Chief Operating Officer Matthew Patterson will make a presentation at the BioCentury NewsMakers in the Biotech Industry Conference on Thursday, September 4, 2008 at 2:30 p.m. EDT in Room 402/403 with a breakout session immediately following the presentation in Room 401. The conference will be held at Millennium Broadway Hotel & Conference Center in New York.

A webcast and audio archive of the presentation will be available at http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 30 days until October 4, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
2. Amicus Therapeutics Announces First Quarter 2008 Financial Results
3. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
5. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
9. Amicus Therapeutics to Host R&D Day
10. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Pittsburgh, PA (PRWEB) , ... May 22, 2017 ... ... Inc. announced today that it is exhibiting in booth B2 at the Association ... in Pittsburgh, May 22-25. , In addition to demonstrating its Cancer Diagnostic ...
(Date:5/21/2017)... CA (PRWEB) , ... May 20, 2017 , ... ... tool that helps avoid the lengthy trial and error process by finding the ... It can also strengthen the doctor-patient relationship through a personalized approach to ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City Science Center ... ripe for commercialization, and who are affiliated with the 21 partner academic and ... QED, now in its tenth round, is the first multi-institutional proof-of-concept program for ...
(Date:5/18/2017)... , ... May 18, 2017 , ... ... The Tapas Cooking Challenge is a two-hour team-building package designed for groups ... created by Chef Jodi Abel, which include items, such as Blackened Shrimp with ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):